References

1. Abramova E.E., Koroleva I.E., Tov N.L. et al. Faktory riska letal’nykh iskhodov u bol’nykh na gemodialize [Risk factors of lethal outcomes at patients on hemodialysis]. Journal of Siberian Medical Sciences, 2015, no. 6, pp. 15–26.
2. Bikbov B.T. Analiz vyzhivaemosti i faktorov riska neblagopriyatnykh iskhodov u bol’nykh na programmnom gemodialize: avtoref. dis. … kand .med. nauk [Survival analysis and risk factors for adverse outcomes in patients on maintenance hemodialysis: Abstract of Doct. Diss.]. Moscow, 2004, 23 p.
3. Bilevich O.A., Ovsнannikov N.V. Otsenka vyzhivaemosti bol’nykh, nakhodyashchikhsya na programmnom gemodialize, v zavisimosti ot pokazatelei funktsional’nogo sostoyaniya serdechno-sosudistoi sistemy [Assessment of survival of patients on program hemodialysis, depending on the indicators of the functional state of the cardiovascular system]. Sovremennye problemy nauki i obrazovaniya [Modern problems of science and education], 2015, no. 6. Available at: http://science-education.ru/ru/article/view?id=23372.
4. Suvorov A.V., Zubeeva G.N., Suslova O.A. et al. Narushenie ritma serdtsa i serdechno-sosudistyi risk u bol’nykh s terminal’noi khronicheskoi pochechnoi nedostatochnost’yu, nakhodyashchikhsya na programmnom gemodialize [The heart rhythm disturbance and cardiovascular risk in patients with terminal chronic renal failure being on hemodialysis]. Prakticheskaya medicina [Practical Medicine], 2013, no. 3, pp. 77–80
5. Araujo S., Lemes H.P., Cunha D.A. et al. Cardiac morphology and function in patients with and without residual diuresis on hemodialysis. J Bras Nefrol., 2011, no. 33(1), pp. 74–81.
6. Amaral S., Hwang W., Fivush B. et al. Serum albumin level and risk for mortality and hospitalization in adolescents on hemodialysis. Clin J Am Soc Nephrol, 2008, no. 3, pp. 759–
7. Balik M., Jabor A., Kolar M. et al. Relationship between natriuretic peptides and residual diuresis during continuous hemodiafiltration. Blood Purif., 2003, no. 21(6), pp. 401–408.
8. Bradbury B.D., Fissell R.B., Albert J.M. et al. Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol, 2007, no. 2, pp. 89–99.
9. Brener Z.Z., Kotanko P., Thijssen S. et al. Clinical benefit of preserving residual renal function in dialysis patients: an update for clinicians. Am J Med Sci., 2010, no. 339(5), pp. 453–456.
10. Chandrashekar A., Ramakrishnan S., Rangarajan D. Survival analysis of patients on maintenance hemodialysis. Indian Journal of Nephrology, 2014, no. 24(4), pp. 206–213.
11. Chandna S.M., Schulz J., Lawrence C. et al. Is there a rationale for rationing chronic dialysis? A hospital based cohort study of factors affecting survival and morbidity. BMJ, 1999, no. 318, pp. 217–223.
12. Chen H.S., Cheng C.T., Hou C.C. et al. Survival and other clinical outcomes of maintenance hemodialysis patients in Taiwan: a 5-year multicenter follow-up study. Hemodialysis international International Symposium on Home. Hemodialysis, 2014, no. 18(4), pp. 799–808.
13. Chen Y., Liu H., Zou J. et al. 24-h residual urine volume at hemodialysis initiation: a possible predictor for acute ischemic stroke incurrence in hemodialysis patients. Clin Neurol Neurosurg., 2013, no. 115(5), pp. 557–561.
14. Chung S.H., Han D.C., Noh H. et al. Risk factors for mortality in diabetic peritoneal dialysis patients. Nephrol Dial Transplant, 2010, no. 25, pp. 3742–3748.
15. Collins A.J., Foley R.N., Herzog C. et al. US Renal Data System 2012 Annual Data Report. (1-476). Am J Kidney Dis., 2013, no. 61, p. 7.
16. Collins A.J., Foley R.N., Gilbertson D.T., Chen S.C. United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease. Kidney Int Suppl., 2015, no. 5(1), pp. 2–7.
17. Combe C., McCullough K.P., Asano Y. et al. Kidney Disease Outcomes Quality Initiative (K/DOQI) and the Dialysis Outcomes and Practice Patterns Study (DOPPS): nutrition guidelines, indicators, and practices. Am J Kidney Dis., 2004, no. 44, pp. 39–46.
18. Cooper B.A., Penne E.L., Bartlett L.H., Pollock C.A. Protein malnutrition and hypoalbumine-mia as predictors of vascular events and mortality in ESRD. Am J Kidney Dis, 2004, no. 43, pp. 61–66.
19. Dalrymple L.S., Mohammed S.M., Mu Y. et al. Risk of cardiovascular events after infection-related hospitalizations in older patients on dialysis. Clin J Am Soc Nephrol, 2011, no. 6(7), pp. 1708–1713.
20. De Mutsert R., Grootendorst D.C., Indemans F. et al. Association between serum albumin and mortality in dialysis patients is partly explained by inflammation, and not by malnutrition. J Ren Nutr., 2009, no. 19, pp. 127–135.
21. Depner T., Daugirdas J., Greene T. et al. Dialysis dose and the effect of gender and body size on outcome in the HEMO Study. Kidney Int., 2004, no. 65, pp.1386–1394.
22. Drew D.A., Sarnak M.J. Ischemic and hemorrhagic stroke: High incidence in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis, 2014, no. 63, pp. 547–548.
23. Eknoyan G., Beck G.J., Cheung A.K. et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med, 2002, no. 347, pp. 2010–2019.
24. Feldman A.M., Combes A., Wagner D. et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol, 2000, no. 35, pp. 537–544.
25. Fleischmann E.H., Bower J.D., Salahudeen A.K. Risk factor paradox in hemodialysis: better nutrition as a partial explanation. Asaio J., 2001, no. 47, pp. 74–81.
26. Fleischmann E., Teal N., Dudley J. et al. Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. Kidney Int., 1999, no. 55, pp. 1560–1567.
27. Fonarow G.C., Chelimsky-Fallick C., Stevenson L.W. et al. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol, 1992, no. 19, pp. 842–850.
28. Foley R.N., Herzog C.A., Collins A.J. Smoking and cardiovascular outcomes in dialysis patients: the United States Renal Data System Wave 2 study. Kidney Int., 2003, no. 63, pp. 1462–1467.
29. Foley R.N., Parfrey P.S., Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. J. Kidney Dis., 1998, no. 32, pp. 112–119.
30. Jung M.Y., Hwang S.Y., Hong Y.A. et al. Optimal hemoglobin level for anemia treatment in a cohort of hemodialysis patients. Kidney research and clinical practice, 2015, no. 34(1), pp. 20–27.
31. Goodkin D.A., Bragg-Gresham J.L., Koenig K.G. et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol., 2003, no. 14, pp. 3270–3277.
32. Grassmann A., Gioberge S., Moeller S., Brown G. ESRD patients in 2004: Global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant., 2005, no. 20, pp. 2587–2593.
33. Hanson J.A., Hulbert-Shearon T.E., Ojo A.O. et al. Prescription of twice-weekly hemodialysis in the USA. Am J Nephrol., 1999, no. 19, pp. 625–633.
34. Hemodialysis Adequacy 2006 Work Group: Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis, 2006, no. 48(1), pp. 2–90.
35. Hsu C.Y., Vittinghoff E., Lin F., Shlipak M.G. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med., 2004, no. 141, pp. 95–101.
36. Iseki K., Shinzato T., Nagura Y. et al. Factors influencing long-term survival in patients on chronic dialysis. Clin Exp Nephrol, 2004, no. 8, p. 89. Available at: https://doi.org/10.1007/s10157-004-0285-z.
37. Kalantar-Zadeh K., Kamranpour N., Kopple J.D. Association between novel HDL inflammatory/anti-inflammatory properties with body mass index in hemodialysis patients. J Am Soc Nephrol., 2004, no. 15, p. 172A.
38. Kalantar-Zadeh K., Kopple J.D., Humphreys M.H., Block G. Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients. Nephrol Dial Transplant, 2004, no. 19, pp. 1507–1519.
39. Kalantar-Zadeh K., Abbott K.C., Salahudeen A.K. et al. Survival advantages of obesity in dialysis patients. Am J Clin Nutr., 2005, no. 81(3), pp. 543–554.
40. Kalantar-Zadeh K., Block G., Humphreys M.H. et al. A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol., 2004, no. 15, pp. 442–453.
41. Kalantar-Zadeh K., Block G., Humphreys M.H., Kopple J.D. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int., 2003, no. 63, pp. 793–808.
42. Kessler M., Zannad F., Lehert P. et al. Predictors of cardiovascular events in patients with end-stage renal disease: An analysis from the Fosinopril in dialysis study. Nephrol Dial Transplant, 2007, no. 22, pp. 3573–3579.
43. Kopple J.D., Zhu X., Lew N.L., Lowrie E.G. Body weight-for-height relationships predict mortality in maintenance hemodialysis patients. Kidney Int., 1999, no. 56, pp. 1136–1148.
44. Kovesdy C.P., Regidor D.L., Mehrotra R. et al. Serum and dialysate potassium concentrations and survival in hemodialysis patients. Clin J Am Soc Nephrol., 2007, no. 2, pp. 999–1007.
45. Liebman S.E., Lamontagne S.P., Huang L.S. et al. Smoking in dialysis patients: a systematic review and meta-analysis of mortality and cardiovascular morbidity. Am J Kidney Dis., 2011, no. 58, pp. 257–265.
46. Lin X., Yan Y., Ni Z. et al. Clinical outcome of twice-weekly hemodialysis patients in shanghai. Blood Purif, 2012, no. 33, pp. 66–72.
47. Locatelli F., Pozzoni P., Tentori F., Del V.L. Epidemiology of cardiovascular risk in patients with chronic kidney disease. Nephrol Dial Transplant, 2003, no. 18, pp. 2–9.
48. Lowrie E.G., Lew N.L. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis., 1990, no. 15, pp. 458–482.
49. Ma T., Ding G. Effects of residual renal function on left ventricle and analysis of related factors in patients with hemodialysis. Ren Fail., 2013, no. 35(2), pp. 198–203
50. Macleod J., Davey Smith G. Psychosocial factors and public health: a suitable case for treatment? J Epidemiol Community Health, 2003. no. 57, pp. 565–570.
51. Mohamed-Ali V., Goodrick S., Bulmer K. et al. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Physiol, 1999, no. 277, pp. 971–975.
52. Mokoli V.M., Sumaili E.K., Lepira F.B. et al. Impact of residual urine volume decline on the survival of chronic hemodialysis patients in Kinshasa. BMC Nephrology, 2016. no. 17, p. 182 https://doi.org/10.1186/s12882-016-0401-9
53. Niebauer J., Volk H.D., Kemp M. et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet, 1999, no. 353, pp. 1838–1842.
54. Nishizawa Y., Shoji T., Ishimura E. et al. Paradox of risk factors for cardiovascular mortality in uremia: is a higher cholesterol level better for atherosclerosis in uremia? Am J Kidney Dis., 2001, no. 38, pp. 4–7.
55. Nakayama M., Metoki H., Terawaki H. et al. Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population-the Ohasama study. Nephrol Dial Transpl., 2007, no. 22, pp. 1910–1915.
56. Obi Y., Rhee C.M., Mathew A.T. et al. Residual kidney function decline and mortality in incident hemodialysis patients. J Am Soc Nephrol., 2016. doi: 10.1681/ASN.2015101142.
57. Owen W.F., Lew N.L., Liu Y. et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med., 1993, no. 329, pp. 1001–1006.
58. Panaput T., Thinkhamrop B., Domrongkitchaiporn S. Dialysis Dose and Risk Factors for Death Among ESRD Patients Treated with Twice-Weekly Hemodialysis: A Prospective Cohort Study. Blood Purif., 2014, no. 38, pp. 253–262. DOI: 10.1159/000368885.
59. Perl J., Bargman J.M. The importance of residual kidney function for patients on dialysis: a critical review. Am J Kidney Dis., 2009, no. 53(6), pp. 1068–1081.
60. Pippias M., Stel V.S., Abad Diez J.M. et al. Renal replacement therapy in Europe: a summary of the 2012 ERA-EDTA Registry Annual Report. Clin Kidney J., 2015, no. 8(3), pp. 248–261.
61. Plantinga L.C., Fink N.E., Levin N.W. et al. Early, intermediate, and long-term risk factors for mortality in incident dialysis patients: The Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study. Am J Kidney Dis., 2007, no. 49, pp. 831–840.
62. Pozzoni P., Del Vecchio L., Pontoriero G. et al. Long-term outcome in hemodialysis: Morbidity and mortality. J Nephrol., 2004, no. 17(8), pp. 87–95.
63. Postorino M., Marino C., Tripepi G., Zoccali C. Calabrian Registry of Dialysis and Transplantation: Prognostic value of the New York Heart Association classification in end-stage renal disease. Nephrol Dial Transplant, 2007, no. 22, pp. 1377–1382.
64. Rauchhaus M., Coats A.J., Anker S.D. The endotoxin-lipoprotein hypothesis. Lancet, 2000, no. 356, pp. 930–933.
65. Salahudeen A.K. Obesity and survival on dialysis. Am J Kidney Dis., 2003, no. 41, pp. 925–932.
66. Salama P., Assefa F., Talley L. et al. Malnutrition, measles, mortality, and the humanitarian response during a famine in Ethiopia. JAMA, 2001, no. 286, pp. 563–571.
67. Shafi T., Jaar B.G., Plantinga L.C. et al. Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. Am J Kidney Dis., 2010, no. 56, pp. 348–358.
68. Tang Y., Brooks J.M., Wetmore J.B., Shireman T.I. Association between higher rates of cardioprotective drug use and survival in patients on dialysis. Res Social Adm Pharm, 2015, no. 11(6), pp. 824–843.
69. Tang W., Li L.X., Pei J., Wang T. Heart rate variability in peritoneal dialysis patients: what is the role of residual renal function? Blood Purif, 2012, no. 34(1), pp. 58–66.
70. Tong J., Liu M., Li H. et al. Mortality and associated risk factors in dialysis patients with cardiovascular disease. Kidney Blood Press Res., 2016, no. 41, pp. 479–487. Available at: https://doi.org/10.1159/000443449
71. United States Renal Data System. Excerpts from USRDS 2008 Annual Data Report. U.S. Department of Health and Human Services. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Am J Kidney Dis., 2009, no. 1.
72. USRDS 2012 Annual Report: National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD, 2012.
73. Vilar E., Farrington K. Emerging importance of residual renal function in end-stage renal failure. Semin Dial, 2011, no. 24(5), pp. 487–494.
74. Wang H.H., Hung S.Y., Sung J.M. et al. Risk of stroke in long-term dialysis patients compared with the general population. Am J Kidney Dis., 2014, 63, pp. 604–611.
75. Wright J.R., Shurrab A.E., Cooper A. et al. Left ventricular morphology and function in patients with atherosclerotic renovascular disease. J Am Soc Nephrol., 2005, no. 16(9), pp. 2746–2753.
76. Wolf M., Shah A., Gutierrez O. et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int., 2007, no. 72, pp. 1004–1013.
77. Wu C.K., Yang Y.H., Juang J.M. et al. Effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in dialysis patients: a nationwide data survey and propensity analysis. Medicine (Baltimore), 2015, no. 94(3), e424.
78. Yamagata K., Nakai S., Iseki K., Tsubakihara Y. Late dialysis start did not affect long-term outcome in Japanese dialysis patients: long-term prognosis from Japanese Society for [corrected] Dialysis Therapy Registry. Ther Apher Dial., 2012, no. 16(2), pp. 111–120.
79. Zager P.G., Nikolic J., Brown R.H. et al. “U” curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int., 1998, no. 54, pp. 561–569.